Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
1999-03-04
2002-04-09
Prouty, Rebecca E. (Department: 1652)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C435S348000, C435S254110, C435S320100, C435S325000, C530S350000, C536S023100, C536S023500
Reexamination Certificate
active
06368846
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal.
BACKGROUND OF THE INVENTION
Bites from ectoparasites, in particular fleas, can cause a hypersensitive response in animals. In particular, hypersensitive responses to fleabites is manifested in a disease called flea allergy dermatitis (FAD). Hypersensitivity refers to a state of altered reactivity in which an animal, having been previously exposed to a compound, exhibits an allergic response to the compound upon subsequent exposures. Hypersensitive responses include immediate and delayed-type hypersensitivity, and in particular Type I, Type II, Type III and Type IV hypersensitivities (described in detail in Janeway et al.,
Immunobiology
, Garland Publishing, New York, 1994, which is incorporated in its entirety by this reference).
Foreign compounds that induce symptoms of immediate and/or delayed hypersensitivity are herein referred to as allergens. The term “allergen” primarily refers to foreign compounds capable of causing an allergic response. The term can be used interchangeably with the term “antigen,” especially with respect to a foreign compound capable of inducing symptoms of immediate and/or delayed hypersensitivity. Factors that influence an animal's susceptibility to an allergen can include a genetic component and/or environmental exposure to an allergen. Animals can be de-sensitized to an allergen by repeated injections of the allergen to which an animal is hypersensitive.
FAD can have manifestations of both immediate and delayed-type hypersensitivity (described in detail in Janeway et al. ibid.). Effective treatment of FAD has been difficult if not impossible to achieve. FAD afflicts about 15% of cats and dogs in flea endemic areas and the frequency is increasing each year. In a geographical area, effective flea control requires treatment of all animals. One treatment investigators have proposed includes desensitization of animals using flea allergens. However, reliable, defined preparations of flea allergens are needed for such treatments.
Until the discovery of the novel formulations of the present invention, flea allergens responsible for FAD had not been clearly defined. Whole flea antigen preparations have been used to diagnose and desensitize animals with FAD (Benjamini et al., 1960, pp. 214-222
, Experimental Parasitology
, Vol. 10; Keep et al., 1967, pp. 425-426
, Australian Veterinary Journal
, Vol. 43; Kristensen et al., 1978, pp. 414-423
, Nord. Vet
-
Med
, Vol. 30; Van Winkle, 1981, pp. 343-354
, J. Amer. Animal Hosp. Assoc
., Vol. 17; Haliwell et al., 1987, pp. 203-213
, Veterinary Immunology and Immunopathology
, Vol. 15; Greene et al., 1993, pp. 69-74
, Parasite Immunology
, Vol. 15); PCT Publication No. WO 93/18788 by Opdebeeck et al.; and Van Winkle, pp. 343-354, 1981
, J. Am. Anim. Hosp. Assoc
., vol. 32. Available commercial whole flea extracts, however, are unpredictable and, therefore, have limited usefulness.
Prior investigators have suggested that products contained in flea saliva might be involved in FAD and have also suggested methods to isolate such products: Benjamini et al., 1963, pp. 143-154
, Experimental Parasitology
, Vol. 13; Young et al., 1963, pp. 155-166
, Experimental Parasitology
13, Vol. 13; Michaeli et al., 1965, pp. 162-170
, J. Immunol
., Vol. 95; and Michaeli et al., 1996, pp. 402-406
, J. Immunol
., Vol. 97. These investigators, however, have characterized the allergenic factors of flea saliva as being haptens having molecular weights of less than 6 kilodaltons (kD). That they are not proteins is also supported by the finding that they are not susceptible to degradation when exposed to strong acids (e.g., 6 N hydrochloric acid) or heat. Some of the particular low molecular weight allergenic factors have also been characterized as being a highly fluorescent aromatic fraction (Young et al., ibid.). In addition, studies by such investigators have indicated that in order to be allergenic, such factors need to be associated with adjuvants and/or carriers, such as collagen or portions of the membrane used to collect the oral secretions. Moreover, the methods described to collect flea saliva factors were difficult and unpredictable. Furthermore the factors isolated by these methods were typically contaminated with material from the fleas, their culture medium or the skin-based membranes used to allow the fleas to feed.
Thus, there remains a need to more clearly define flea saliva allergens capable of inducing a hypersensitive response in animals. In addition, there remains a need to develop a method to collect substantially pure flea saliva allergens which provide predictable and less expensive preparations of allergens useful for desensitizing animals subject to, or having, FAD.
SUMMARY OF THE INVENTION
One embodiment of the present invention is an isolated nucleic acid molecule that hybridizes under stringent conditions with a gene including a flea saliva gene comprising a nucleic acid sequence including SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:76 and a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:78 and SEQ ID NO:87.
The present invention also includes a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence encoding a protein comprising an amino acid sequence including SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78 and SEQ ID NO:87.
Another embodiment of the present invention includes an isolated protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence encoding a protein comprising an amino acid sequence including SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:65, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78 and SEQ ID NO:87.
Also included in the present invention are recombinant molecules and cells having a nucleic acid molecule of the present invention.
Another aspect of the present invention includes an antibody capable of selectively binding to an ectoparasite protein, or mimetope.
Yet another embodiment of the present invention is a therapeutic composition for treating allergic dermatitis comprising a formulation comprising at least one isolated ectoparasite saliva protein, wherein said ectoparasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence including SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:76 and a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NO:78 and SEQ ID NO:87. A preferred therapeutic composition of the present invention also includes an excipient, an adjuvant and/or a carrier. Also included in the present invention is a method to desensitize a host animal to allergic dermatitis. The method includes the step of administering to the animal a therapeutic composition of the present invention.
Other embodiments of the present invention include methods to identify an animal susceptible to or having allergic dermatitis, using in vivo or in vitro methods. In one embodiment, an animal susceptible to or having allergic dermatitis is identified in vivo by the method comprising: (a) administering to a site on the animal a formulation comprising at least one isolated ectoparasit
Hunter Shirley Wu
Sim Gek-Kee
Weber Eric R.
Heska Corporation
Prouty Rebecca E.
Sheridan & Ross P.C.
Steadman David J.
LandOfFree
Ectoparasite saliva proteins and apparatus to collect such... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ectoparasite saliva proteins and apparatus to collect such..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ectoparasite saliva proteins and apparatus to collect such... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2867123